2020 IPO

Beam Therapeutics Stock

Developer of genome editing technologies.

Sign up today and learn more about Beam Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

ARCH Venture Partners


Cambridge MA, US

Total Funding


About Beam Therapeutics Stock

Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.


Funding History

April 2018$13.0M
May 2018$74.0M



J. Keith Joung

Chief Scientific Officer

Giuseppe Ciaramella


David R. Liu

Co-Founder and Board Member

Feng Zhang

Chief Executive Officer and Board Member

John Evans


Global University Venturing - May, 15 2018

Beam Therapeutics lasers in on $87m series A

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: